Mankind Pharma Limited (MANKIND) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹2,668.3 (+3.31% day change)
Key ratios
- P/E ratio
- 57.57
- P/B ratio
- 5.08
- ROE (%)
- 11.74
- ROCE (%)
- 12.66
- Debt/Equity
- 0.39
- Dividend yield (%)
- 0.05
- Market cap (₹ Cr)
- 110,212.82
Forensic checks
Piotroski F-Score: 5/9 · Altman Z-Score: 7.1 · Beneish M-Score: -2.39
InvestSights quality score
63.8/100 — Above Average (descriptive data-driven composite; not a recommendation)
Latest earnings call (Q2 FY27)
AI summary: The most important signal was the broadening recovery in Mankind’s core domestic prescription business, particularly the acceleration in volume growth to 6.2% in Q2 FY27 and secondary-sales growth of 15.7%, ahead of IPM growth of 14.2% excluding tirzepatide. Management linked this improvement to stabilised leadership and field teams, stronger chronic execution, acute recovery…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.